Were physicians/patients aware of the change in the formulation? [BE/BA News]

posted by Helmut Homepage – Vienna, Austria, 2017-11-26 17:37 (1642 d 01:33 ago) – Posting: # 18010
Views: 7,265

Hi nobody,

» L-Thyroxine (as an endogenous aminoacid with strong hormonal effects) is somefing very special, as recognized long ago, e.g.: […]

Sure. Dose finding for levothyroxine is a pain in the back (NTID, long half life, large between-subject variability). Hence, most endocrinologists would not switch their patients from one product to another one.
Note that the FDA’s guidance is even less stringent than the EMA’s. In the study of Gottwald-Hostalek et al. the CVintra of Cmax was 17.7%. According to the FDA’s RSABE (assuming CVwT=CVwR) that would translate into implied BE-limits of 83.11–120.33%…
I think that neither physicians nor patients were aware of what was going on – that wasn’t a product-switch but a change in the formulation. Both thought to take still the same product of the same manufacturer.

Dif-tor heh smusma 🖖 [image]
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
 Admin contact
22,105 posts in 4,630 threads, 1,566 registered users;
online 3 (1 registered, 2 guests [including 2 identified bots]).
Forum time: Thursday 20:11 CEST (Europe/Vienna)

Operational hectic replaces
intellectual calms.    Alexander Huiskes

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz